pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-210 |
Genomic Coordinates | chr11: 568089 - 568198 |
Synonyms | MIRN210, mir-210, MIR210 |
Description | Homo sapiens miR-210 stem-loop |
Comment | This human miRNA was predicted by computational methods using conservation with mouse and Fugu rubripes sequences . |
RNA Secondary Structure | ![]() |
Associated Diseases | ![]() |
Mature miRNA Information | ||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-210-3p | |||||||||||||||||||||||||||||||||||||||
Sequence | 66| CUGUGCGUGUGACAGCGGCUGA |87 | |||||||||||||||||||||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||||||||||||||||||||
Experiments | Cloned | |||||||||||||||||||||||||||||||||||||||
Editing Events in miRNAs |
|
|||||||||||||||||||||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Biomarker Information |
|
---|
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | DYRK2 | ||||||||||||||||||||
Synonyms | - | ||||||||||||||||||||
Description | dual specificity tyrosine phosphorylation regulated kinase 2 | ||||||||||||||||||||
Transcript | NM_003583 | ||||||||||||||||||||
Other Transcripts | NM_006482 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on DYRK2 | |||||||||||||||||||||
3'UTR of DYRK2 (miRNA target sites are highlighted) |
>DYRK2|NM_003583|3'UTR 1 GCTCACGTCCCCTGATGCTGGTAACCTGAAAGATACGACATTGCTGAGCCTTACTGGGTTGAAAAGGAGTAGCTCAGACC 81 TGTTTTTATTTGCTCAATAACTCTACTCATTTGTATCTTTTCAGCACTTAATTTTAATGTAAGAAAGTTGTTCATTTTGT 161 TTTTATAAAATACATGAGGACAATGCTTTAAGTTTTTATACTTTCAGAAACTTTTTGTGTTCTAAAAGTACAATGAGCCT 241 TACTGTATTTAGTGTGGCAGAATAATAACATCAGTGGCAGGCCACTGATTACTTCATGACTGCCACGCATTTACAGATTG 321 GTGTCAAAGACATTCACTATGTTTTTATGGTTCATGTTATATCCTCCCCAGGGTGACAGCCCCTTAAGGCCCTCCTTTTC 401 CCTCCATGCTCCAGGTCCATGCACAGGTGTAGCATGTCCTGCTTCCGTTTTTCATAAATTAATCTGGGTGTTGGGGGTAG 481 TGGGAGGAGAACGGTCAGAATCAAAGTGACATTCTAAGAAAAACTGTACCTTAGAGATTTTCCTCTAGTGCTCAAACAAA 561 TACAAAATAAGATCCCCAAGGTTTAAACTGCCCAGTTAGCATTCTGACATTCTAAAAGCCGGCAAAGCAGCTTTTAGTGG 641 ATAAATGGGAATGGAAACGTGTGTGTTCCTCCAAATTTTCTAGTATGATCGGTGAGCTGTTTTGTAAAGAAGCCTCATAT 721 TACAGAGTTGCTTTTGCACCTAAATTTAGAATTGTATTCCATGAACTGTTCCTCCCTTTTCTCTGCTTTTCTCCTCTCTG 801 TTCCTCTTTTAATACCACACGTCTGTTGCTTGCATTTAGTTTGTCTTCTTCCTTCAGCTGTGTATCCCAGACTGTTAATA 881 CAGAAAAGAGACATTTCAGCTGTGATTATGACCATTGTTTCATATTCCAATTAAAAAAAGAACAGCAGCCTAGCTACTTA 961 AGGTGGGGATTTCCATAGTTCCAAAGAAGATTTAGCAGATTAGAGTGAGTTCACACTTTTCAGGTGCCACTGTAAGGTTC 1041 TCTCAGCCTGGGAAACTATCAACTCTTTCTTTAAAAAGAAAGAGGGTTGAAAATCCTCTGGACGAACAGAAGTCACTTTG 1121 GCTGTTCAGTAAGGCCAATGTTAACAACACGTTTAGAGGAGGAAAAGTTCAACCTCAAGTTAAATGGTTTGACTTATTCT 1201 TCGTATCATTAGAAGAACCCCAGAGATAGCATTCCTCTATTTTATTTTACTTTCTTTTGGATTGCACTGATTGTTTTTGT 1281 GGGAATGACACTTTATCTGGCAAAGTAACTGAGAGTTTGGTAAAAGAATATTTTCTTCTCTGAATAATAATTATTTTCAC 1361 AGTGAAAATTTCAGTATTTTATCACTAATGTATGAGCAATGATCTATATCAATTTCAAGGCACGTGAAAAAAATTTTTTA 1441 GTATGTGCAATTTAATATAGAAAGATTTCTGCCTGTTTGGACAATAGGTTTTGGGTAGTACAGATTAGGATAAGTAAGCT 1521 TATATATGCACAGAGATTATTGTATTACCTGTAAATTGATTTACAAGTACTTAAAAGCGTGGTCCCCAGTGAGGCCAAGA 1601 AAGTTTCCGGTTAAGTTCTTTAATAATAATCCTACAGTTTATCTTAAGAAAAAAAAAAAGGTTTGAAAAAAACACTTTAA 1681 TTTAGGCTTCGTTGGTTGATGGTGGAAAAAAATGCTCAGGAAATATTTCAGATATTTGCCAAAAAACCAGTAATAAGGTT 1761 ACCTTATTAAAATAGTGATATTTGCTTTACTATTTAAGGTGTCACTGATAAATTAATTTGTACTTCTGTGTTTAGAAATT 1841 ATAGCTTCTTTTCCCTTAGTCAAATTTTTTAGCATATTATACACATTTCTGTGTAATCTGTGGAAGTGCAATAATATGTT 1921 AGTAAGTTACATTTTAAATAATGCTCATGTGACAATACTCCCAATCAATGGCTTATAGAATTTAAAGATCTGTATATTAG 2001 ATTTTGGCTTAAAGGCATGAGAAGTATAAGACTTGGTTTGGTGGCTTTGTAAGACCACCAGCCTCTTAATGATGGTTAGC 2081 TTCTTTAGGTCATTAAATCAATAAAAACATATAATGCTGTTTTGCTCTTCTAATGCTCCTCTTCCATTTCCAGTTATCTT 2161 CACATTTACATTTAAATATACAAACCTGAGCCTGCCATTATTAATTTCCCTATAAAATGACGATACATGTGAACATTTAT 2241 AAATGGACTAATACTGCTTGTCTTTCCCCCACCGCACAAAACTGGTTCTTAAGATGCCAGCAATGAATTTGAGACTATCT 2321 TTATTTATAAATGGAAACCGGAAACTTTTATACCAAACTATAATAATGTGCAGCACTGTAGGGCTTTTTTTTTTTTCCCT 2401 CCAAATACAGTGAAATTTTTTTATTCACAAGAGCTGCCACATCTCAGCATTTAGTAATAGAGCTGCTTTAATAAAATTCT 2481 AGTTTGATTGTCATGTCAAAAAAAGAAAAATGTTGCATCTTTGTGATTTTAAAACATAAATTAATGAAGGCTCTGATAGG 2561 CTATTAGGAGTTGGCTTGGAAACAGTTTTTGGTCTCACAGGTTACCATTGTTTGGGGATGTCTGAGCTGTTTTCAGATCT 2641 AGGAATAGCACAGTGTTGTCTTGTCTTTGGCAGTCTCATTTGGCTCTGTTTCTTGCACCACCAGCGTGTTCATTACCACT 2721 TAAATATATTGCTACAGCAGTGGAACAACAGAGTGGTGCAAGACACTGTAGATTAACGGTAGAGGAGAAATTGTGCCCTT 2801 AGTGTTAACAATGTGCCTTTTGTTCTGAATGCCATGTTGTAGGGCATGCATTTTTTGGCCTCTTTAACTCTTCGAATTCT 2881 AGTCAGTAAGAATGGAACCCATCTCTGCAAAGATACATCTGTCTTAAATATCTAGTTACAGGCCTTAATAGAAACCATAA 2961 GGCATGACTCATCTTCAGGCACTGAAAAAAGATAACCATCAGGTAGTGTTACACAAGGACTTCCTATATTTAAGGGGTTA 3041 AAGATGGTCTTTGTTGTATCTTAACATCAGACTGATTTTTACATTTTTTTTTTGTTATGCTAACACTAGACAAAAATCAA 3121 CTGTATTTGTAAAAATTTACCTCAAACCATTTAATTTTATAGTGTGATTAATCCCAGGGCATTTGGTATGAACCAAAGTG 3201 CATTCCTTTTATATGTGCCTGGCTCTAGTAAGGATGGCCAGGGATTTTTACAATTTGGGTGCAAGGCACTTAAGCCACTT 3281 TTAAACTTAATGGGTGGTTTGGGGTCGTGTTAAATGACTCCATCAGAATGTTAGAAAACACTTTAGGCATCAGTAGCATT 3361 GGGCCATATTGGAATCCTAAAGTGTGAATTATTTTAAGGAGAGCATTCATTTTTGTAATTTTTTTCATCAAAAATATTTC 3441 TGGTAAGCAGAAGACTTTTTAAAAAAACTGATCTGGTCTCGGTAAAGGTTTTAATATTGCCCAACATAATGCTGTAATAG 3521 CATTAAAAAAAGTATTTGTGAACTCTGTTTCTTAGGGGCTTGTACATCTCTCTGCTATGGACATACATAAAATTAATTGT 3601 AATTATACTCAGCTCAACTGCTACAGTTCTGTCTAGGCAGTGGCTTGGGTTTTTATCGAGCAACAACTTAGACACGTGAC 3681 TGTAATATGCTGCAACTGTGTGTACTGAAAATATGTGAAAATGGTTGAATGTGGACTGTGTATATATGTATGTAAAAATT 3761 TCTGTGAGATGCTGCTGTCGCCACTTAACATTAAATATGTTCTAGTGGATTTTAATCCTAGTGGCCAGTTCTATGATACT 3841 GTATGTATTATACAGCTGATGACAGGAGTAAGACTGTTTAGTGAATATCTGTTAAATTTTATTGTTGTGGCCAGAGATAA 3921 TTTCAGAATAAAATTTTAATGTCCTACCTTA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | TZM-bl | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM1462574. RNA binding protein: AGO2. Condition:TZM-bl ami BaL
... - Whisnant AW; Bogerd HP; Flores O; Ho P; et al., 2013, mBio. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Whisnant AW; Bogerd HP; Flores O; Ho P; et al. - mBio, 2013
UNLABELLED: The question of how HIV-1 interfaces with cellular microRNA (miRNA) biogenesis and effector mechanisms has been highly controversial. Here, we first used deep sequencing of small RNAs present in two different infected cell lines (TZM-bl and C8166) and two types of primary human cells (CD4(+) peripheral blood mononuclear cells [PBMCs] and macrophages) to unequivocally demonstrate that HIV-1 does not encode any viral miRNAs. Perhaps surprisingly, we also observed that infection of T cells by HIV-1 has only a modest effect on the expression of cellular miRNAs at early times after infection. Comprehensive analysis of miRNA binding to the HIV-1 genome using the photoactivatable ribonucleoside-induced cross-linking and immunoprecipitation (PAR-CLIP) technique revealed several binding sites for cellular miRNAs, a subset of which were shown to be capable of mediating miRNA-mediated repression of gene expression. However, the main finding from this analysis is that HIV-1 transcripts are largely refractory to miRNA binding, most probably due to extensive viral RNA secondary structure. Together, these data demonstrate that HIV-1 neither encodes viral miRNAs nor strongly influences cellular miRNA expression, at least early after infection, and imply that HIV-1 transcripts have evolved to avoid inhibition by preexisting cellular miRNAs by adopting extensive RNA secondary structures that occlude most potential miRNA binding sites. IMPORTANCE: MicroRNAs (miRNAs) are a ubiquitous class of small regulatory RNAs that serve as posttranscriptional regulators of gene expression. Previous work has suggested that HIV-1 might subvert the function of the cellular miRNA machinery by expressing viral miRNAs or by dramatically altering the level of cellular miRNA expression. Using very sensitive approaches, we now demonstrate that neither of these ideas is in fact correct. Moreover, HIV-1 transcripts appear to largely avoid regulation by cellular miRNAs by adopting an extensive RNA secondary structure that occludes the ability of cellular miRNAs to interact with viral mRNAs. Together, these data suggest that HIV-1, rather than seeking to control miRNA function in infected cells, has instead evolved a mechanism to become largely invisible to cellular miRNA effector mechanisms.
LinkOut: [PMID: 23592263]
|
CLIP-seq Support 1 for dataset GSM1462574 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | TZM-bl / TZM-bl ami BaL |
Location of target site | ENST00000344096.3 | 3UTR | UCUUUCCCCCACCGCACAAAACUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23592263 / GSE59944 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
126 hsa-miR-210-3p Target Genes:
Functional analysis:
ID![]() |
Target | Description | Validation methods |
![]() |
![]() |
|||||||
Strong evidence | Less strong evidence | |||||||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|||||
MIRT000149 | HOXA9 | homeobox A9 | ![]() |
![]() |
![]() |
![]() |
4 | 1 | ||||
MIRT000150 | TP53I11 | tumor protein p53 inducible protein 11 | ![]() |
![]() |
2 | 1 | ||||||
MIRT000151 | PIM1 | Pim-1 proto-oncogene, serine/threonine kinase | ![]() |
![]() |
2 | 1 | ||||||
MIRT000152 | HOXA1 | homeobox A1 | ![]() |
![]() |
2 | 1 | ||||||
MIRT000153 | FGFRL1 | fibroblast growth factor receptor like 1 | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
6 | 3 | ||
MIRT000156 | RAD52 | RAD52 homolog, DNA repair protein | ![]() |
![]() |
![]() |
![]() |
![]() |
5 | 3 | |||
MIRT001930 | NPTX1 | neuronal pentraxin 1 | ![]() |
![]() |
![]() |
3 | 2 | |||||
MIRT002024 | EFNA3 | ephrin A3 | ![]() |
![]() |
8 | 8 | ||||||
MIRT003153 | BDNF | brain derived neurotrophic factor | ![]() |
![]() |
![]() |
![]() |
![]() |
5 | 1 | |||
MIRT003154 | PTPN1 | protein tyrosine phosphatase, non-receptor type 1 | ![]() |
![]() |
![]() |
![]() |
![]() |
5 | 1 | |||
MIRT003155 | P4HB | prolyl 4-hydroxylase subunit beta | ![]() |
![]() |
6 | 2 | ||||||
MIRT003156 | UBQLN1 | ubiquilin 1 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003157 | SERTAD2 | SERTA domain containing 2 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003158 | SEH1L | SEH1 like nucleoporin | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003159 | NCAM1 | neural cell adhesion molecule 1 | ![]() |
![]() |
![]() |
![]() |
4 | 1 | ||||
MIRT003160 | MID1IP1 | MID1 interacting protein 1 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003161 | MDGA1 | MAM domain containing glycosylphosphatidylinositol anchor 1 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003162 | KIAA1161 | myogenesis regulating glycosidase (putative) | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003163 | ISCU | iron-sulfur cluster assembly enzyme | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
6 | 7 | ||
MIRT003164 | HOXA3 | homeobox A3 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003165 | GPD1L | glycerol-3-phosphate dehydrogenase 1 like | ![]() |
![]() |
![]() |
7 | 2 | |||||
MIRT003166 | DENND6A | DENN domain containing 6A | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003167 | CPEB2 | cytoplasmic polyadenylation element binding protein 2 | ![]() |
![]() |
![]() |
![]() |
![]() |
5 | 1 | |||
MIRT003168 | CDK10 | cyclin dependent kinase 10 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003169 | ABCB9 | ATP binding cassette subfamily B member 9 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003170 | CBX1 | chromobox 1 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003171 | XIST | X inactive specific transcript (non-protein coding) | ![]() |
![]() |
![]() |
![]() |
4 | 1 | ||||
MIRT003172 | TNPO1 | transportin 1 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003173 | SMCHD1 | structural maintenance of chromosomes flexible hinge domain containing 1 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003174 | PTAR1 | protein prenyltransferase alpha subunit repeat containing 1 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003175 | NIPBL | NIPBL, cohesin loading factor | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003176 | MIB1 | mindbomb E3 ubiquitin protein ligase 1 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003177 | HECTD1 | HECT domain E3 ubiquitin protein ligase 1 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003178 | ELK3 | ELK3, ETS transcription factor | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003179 | DDAH1 | dimethylarginine dimethylaminohydrolase 1 | ![]() |
![]() |
![]() |
![]() |
4 | 1 | ||||
MIRT003180 | CLASP2 | cytoplasmic linker associated protein 2 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003181 | CHD9 | chromodomain helicase DNA binding protein 9 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003182 | ATP11C | ATPase phospholipid transporting 11C | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003183 | APC | APC, WNT signaling pathway regulator | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003184 | E2F3 | E2F transcription factor 3 | ![]() |
![]() |
![]() |
7 | 5 | |||||
MIRT003185 | ACVR1B | activin A receptor type 1B | ![]() |
![]() |
2 | 1 | ||||||
MIRT003916 | MRE11A | MRE11 homolog, double strand break repair nuclease | ![]() |
![]() |
2 | 1 | ||||||
MIRT003917 | XPA | XPA, DNA damage recognition and repair factor | ![]() |
![]() |
2 | 1 | ||||||
MIRT004672 | MNT | MAX network transcriptional repressor | ![]() |
![]() |
![]() |
![]() |
4 | 2 | ||||
MIRT006326 | AIFM3 | apoptosis inducing factor, mitochondria associated 3 | ![]() |
![]() |
![]() |
3 | 2 | |||||
MIRT006519 | CASP8AP2 | caspase 8 associated protein 2 | ![]() |
![]() |
![]() |
![]() |
4 | 1 | ||||
MIRT006663 | VMP1 | vacuole membrane protein 1 | ![]() |
![]() |
![]() |
3 | 2 | |||||
MIRT006830 | TFRC | transferrin receptor | ![]() |
![]() |
![]() |
3 | 2 | |||||
MIRT047002 | PFDN2 | prefoldin subunit 2 | ![]() |
1 | 1 | |||||||
MIRT047003 | U2AF2 | U2 small nuclear RNA auxiliary factor 2 | ![]() |
1 | 1 | |||||||
MIRT047004 | UBA1 | ubiquitin like modifier activating enzyme 1 | ![]() |
1 | 1 | |||||||
MIRT047005 | ESPL1 | extra spindle pole bodies like 1, separase | ![]() |
1 | 1 | |||||||
MIRT047006 | ACTR1A | ARP1 actin related protein 1 homolog A | ![]() |
1 | 1 | |||||||
MIRT047007 | SCN1B | sodium voltage-gated channel beta subunit 1 | ![]() |
1 | 1 | |||||||
MIRT047008 | RCC2 | regulator of chromosome condensation 2 | ![]() |
1 | 1 | |||||||
MIRT053179 | HSD17B1 | hydroxysteroid 17-beta dehydrogenase 1 | ![]() |
![]() |
2 | 1 | ||||||
MIRT054098 | NDUFA4 | NDUFA4, mitochondrial complex associated | ![]() |
![]() |
![]() |
![]() |
4 | 2 | ||||
MIRT054099 | SDHD | succinate dehydrogenase complex subunit D | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
6 | 4 | ||
MIRT054141 | STMN1 | stathmin 1 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT054142 | DIMT1L | DIM1 dimethyladenosine transferase 1 homolog | ![]() |
![]() |
![]() |
![]() |
4 | 2 | ||||
MIRT054186 | ROD1 | polypyrimidine tract binding protein 3 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT054203 | ALDH5A1 | aldehyde dehydrogenase 5 family member A1 | ![]() |
![]() |
![]() |
![]() |
4 | 1 | ||||
MIRT054204 | FOXN3 | forkhead box N3 | ![]() |
![]() |
![]() |
![]() |
![]() |
5 | 2 | |||
MIRT054205 | MCM3 | minichromosome maintenance complex component 3 | ![]() |
![]() |
![]() |
![]() |
4 | 1 | ||||
MIRT054206 | IGFBP3 | insulin like growth factor binding protein 3 | ![]() |
![]() |
6 | 2 | ||||||
MIRT054207 | COL4A2 | collagen type IV alpha 2 chain | ![]() |
![]() |
6 | 2 | ||||||
MIRT054208 | INPP5A | inositol polyphosphate-5-phosphatase A | ![]() |
![]() |
![]() |
![]() |
4 | 1 | ||||
MIRT054209 | EHD2 | EH domain containing 2 | ![]() |
![]() |
![]() |
![]() |
4 | 1 | ||||
MIRT054210 | SH3BGRL | SH3 domain binding glutamate rich protein like | ![]() |
![]() |
![]() |
![]() |
![]() |
5 | 2 | |||
MIRT054248 | PTPN2 | protein tyrosine phosphatase, non-receptor type 2 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT054321 | LDHA | lactate dehydrogenase A | ![]() |
![]() |
2 | 1 | ||||||
MIRT054324 | LDHB | lactate dehydrogenase B | ![]() |
![]() |
2 | 1 | ||||||
MIRT054349 | HIF1A | hypoxia inducible factor 1 alpha subunit | ![]() |
![]() |
![]() |
5 | 2 | |||||
MIRT054714 | FOXP3 | forkhead box P3 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT054794 | HIF3A | hypoxia inducible factor 3 alpha subunit | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT115688 | MGRN1 | mahogunin ring finger 1 | ![]() |
![]() |
2 | 3 | ||||||
MIRT170674 | INSIG1 | insulin induced gene 1 | ![]() |
1 | 1 | |||||||
MIRT437785 | BNIP3 | BCL2 interacting protein 3 | ![]() |
![]() |
![]() |
5 | 2 | |||||
MIRT438739 | KCMF1 | potassium channel modulatory factor 1 | ![]() |
1 | 1 | |||||||
MIRT439407 | TNPO3 | transportin 3 | ![]() |
1 | 1 | |||||||
MIRT439629 | SIPA1L3 | signal induced proliferation associated 1 like 3 | ![]() |
1 | 1 | |||||||
MIRT439632 | SIN3A | SIN3 transcription regulator family member A | ![]() |
1 | 1 | |||||||
MIRT439740 | RPL22 | ribosomal protein L22 | ![]() |
1 | 1 | |||||||
MIRT439886 | PSAP | prosaposin | ![]() |
1 | 1 | |||||||
MIRT439918 | PPP1R2 | protein phosphatase 1 regulatory inhibitor subunit 2 | ![]() |
1 | 1 | |||||||
MIRT439928 | POU2AF1 | POU class 2 associating factor 1 | ![]() |
1 | 1 | |||||||
MIRT440033 | ICMT | isoprenylcysteine carboxyl methyltransferase | ![]() |
![]() |
2 | 3 | ||||||
MIRT440255 | MEF2D | myocyte enhancer factor 2D | ![]() |
1 | 1 | |||||||
MIRT440491 | HMGCS1 | 3-hydroxy-3-methylglutaryl-CoA synthase 1 | ![]() |
![]() |
2 | 3 | ||||||
MIRT440570 | GIT2 | GIT ArfGAP 2 | ![]() |
1 | 1 | |||||||
MIRT440647 | FCHSD2 | FCH and double SH3 domains 2 | ![]() |
1 | 1 | |||||||
MIRT440830 | DEAF1 | DEAF1, transcription factor | ![]() |
1 | 1 | |||||||
MIRT440866 | CSNK1E | casein kinase 1 epsilon | ![]() |
1 | 1 | |||||||
MIRT472232 | NFIC | nuclear factor I C | ![]() |
![]() |
2 | 2 | ||||||
MIRT473190 | MITF | melanogenesis associated transcription factor | ![]() |
![]() |
2 | 2 | ||||||
MIRT477856 | DYRK2 | dual specificity tyrosine phosphorylation regulated kinase 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT497528 | ZNF607 | zinc finger protein 607 | ![]() |
![]() |
2 | 2 | ||||||
MIRT509770 | SERTM1 | serine rich and transmembrane domain containing 1 | ![]() |
![]() |
2 | 6 | ||||||
MIRT524407 | CNTNAP5 | contactin associated protein like 5 | ![]() |
![]() |
2 | 4 | ||||||
MIRT535209 | PKIA | cAMP-dependent protein kinase inhibitor alpha | ![]() |
![]() |
2 | 4 | ||||||
MIRT554511 | RUNX1T1 | RUNX1 translocation partner 1 | ![]() |
![]() |
2 | 4 | ||||||
MIRT558069 | ESCO2 | establishment of sister chromatid cohesion N-acetyltransferase 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT572273 | KCNJ6 | potassium voltage-gated channel subfamily J member 6 | ![]() |
![]() |
2 | 2 | ||||||
MIRT574255 | DOCK7 | dedicator of cytokinesis 7 | ![]() |
![]() |
2 | 4 | ||||||
MIRT575621 | Foxn3 | forkhead box N3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT575742 | Zfp618 | zinc finger protein 618 | ![]() |
1 | 1 | |||||||
MIRT609050 | VAMP4 | vesicle associated membrane protein 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT611143 | TNRC6B | trinucleotide repeat containing 6B | ![]() |
![]() |
2 | 4 | ||||||
MIRT699226 | SLCO3A1 | solute carrier organic anion transporter family member 3A1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT703060 | GTDC1 | glycosyltransferase like domain containing 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT716005 | ASB11 | ankyrin repeat and SOCS box containing 11 | ![]() |
![]() |
2 | 2 | ||||||
MIRT731682 | BTK | Bruton tyrosine kinase | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT733090 | DLEU2L | deleted in lymphocytic leukemia 2-like | ![]() |
![]() |
![]() |
3 | 0 | |||||
MIRT733091 | BRCA2 | BRCA2, DNA repair associated | ![]() |
![]() |
![]() |
3 | 0 | |||||
MIRT733156 | ITGA5 | integrin subunit alpha 5 | ![]() |
1 | 0 | |||||||
MIRT733501 | GATA1 | GATA binding protein 1 | ![]() |
![]() |
![]() |
3 | 0 | |||||
MIRT733503 | SMAD2 | SMAD family member 2 | ![]() |
![]() |
![]() |
3 | 0 | |||||
MIRT733525 | MIR210HG | MIR210 host gene | ![]() |
![]() |
2 | 0 | ||||||
MIRT733615 | TGFBI | transforming growth factor beta induced | ![]() |
![]() |
2 | 0 | ||||||
MIRT734175 | KRAS | KRAS proto-oncogene, GTPase | ![]() |
![]() |
2 | 0 | ||||||
MIRT734293 | PTEN | phosphatase and tensin homolog | ![]() |
1 | 0 | |||||||
MIRT734568 | STAT6 | signal transducer and activator of transcription 6 | ![]() |
1 | 0 | |||||||
MIRT734966 | ADAMTS6 | ADAM metallopeptidase with thrombospondin type 1 motif 6 | ![]() |
1 | 0 | |||||||
MIRT736294 | ID2 | inhibitor of DNA binding 2, HLH protein | ![]() |
1 | 0 | |||||||
MIRT737104 | FABP4 | fatty acid binding protein 4, adipocyte | ![]() |
![]() |
![]() |
3 | 0 | |||||
MIRT756028 | NTN4 | netrin 4 | 3 | 1 |
miRNA-Drug Associations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|